How Mark Cuban is Turning the Prescription Drug Industry Upside Down

When Mark Cuban enters an industry, he typically disrupts it in one way or another. And that’s precisely what it appears he has done once again, though this time in the healthcare space. His Cost Plus Drug Company has turned the industry on its head and introduced transparency to the previously opaque area of prescription drug prices.

“We started [Mark Cuban Cost Plus Drug Company] with the goal of being the low-cost provider for generic drugs,” Cuban told MarketScale. 

The company’s website features a chart displaying the stark difference in the retail price of these drugs versus what consumers pay through their platform. But perhaps the most striking thing about the Cost Plus Drug Company is the clarity of the pricing structure. Leadership has been vocal, on the site and on social media, about how Cost Plus Drugs gets to its final prices in an effort to set a new standard for patient-focused transparency.

For example, every drug is priced with the same markups: a 15% markup supports operations, a $3 charge covers pharmacy labor, and then the usual fixed and variable costs of shipping round out the total. Some savings are minimal; a 60-count of 20mg Fluoxetine, the generic alternative for depression and OCD treatment drug Prozac, costs $4.80 for a Cost Plus Drugs customer, compared to the retail price of $43.80.

Some savings are so stark that they warrant a double take. For a 30-count of 400mg Imatinib, the generic version of leukemia-treatment drug Gleevec, Cost Plus Drugs customers pay $47.50, compared to the retail price of $9,657.40, an enormous difference in cost.

“We will do whatever it takes to get affordable pharmaceuticals to patients,” said Alex Oshmyansky, CEO of Mark Cuban Cost Plus Drug. “The markup on potentially lifesaving drugs that people depend on is a problem that can’t be ignored. It is imperative that we take action and help expand access to these medications for those who need them most.”

With this cost savings business model, underinsured or uninsured patients who’d be paying close to or full price would see the most immediate benefits. Even insured patients though, according to the company’s site, would pay “less than what you would pay when using your insurance at a typical pharmacy.”

The cost of drugs in the United States has been a problem for some time, garnering attention from President Biden and putting a financial strain on many Americans. According to Kevin Stevenson, Director of Strategic Operations at Providence Healthcare Network in Waco, TX, affecting positive change in this side of the industry is critical, as for patients, it’s truly a life or death situation.

“People who don’t have insurance that are paying out of pocket, oftentimes they skip medications because they take food out of their family’s mouth,” Stevenson said.

The high-profile attention that Cuban’s company, as well as the issue at-large, is getting could be a sign of things to come for healthcare in the United States.

“I think we’re seeing people in healthcare now that are having that more entrepreneurial mindset, that are looking at problems and saying how can we look at it from a different viewpoint to try to solve this,” he said.

Stevenson admitted that change in healthcare can come slowly, but with sharks like Mark Cuban in the water, change could be coming sooner rather than later. 

Follow us on social media for the latest updates in B2B!

Image

Latest

purpose
Elevate Your Career Journey by Choosing Purpose, Practicing Intentionality, and Building a Culture of Belonging
November 19, 2025

Purpose doesn’t just shape what we do—it shapes how we grow. When we choose to move through our careers with intention, we start noticing the moments that build trust, the conversations that deepen understanding, and the relationships that elevate our impact. This episode of Professional Quotient digs into what it really means to show up…

Read More
Christie Linebarger
Christie Linebarger’s Journey to Leadership: Grit, Growth & Leading with Heart
November 19, 2025

Leadership conversations are shifting as companies navigate rapid change, tighter labor markets, and evolving employee expectations. Teams want leaders who show up with humility, clarity, and a genuine investment in people—traits that can’t be faked and can’t be automated. And with studies consistently linking team engagement to the quality of direct leadership, understanding how effective…

Read More
Detroit's workforce
Powering Up Detroit’s Workforce: How Per Scholas Is Connecting Local Talent to Tech and Energy Careers
November 18, 2025

Detroit is undergoing a once-in-a-generation transformation—one driven by innovation, community leadership, and an urgent demand for a new kind of workforce. As energy and tech sectors accelerate, organizations and employers are racing to prepare Detroit’s workforce for jobs that didn’t exist a decade ago. Workforce researchers note that tech-enabled roles across industries are growing…

Read More
robot
Robots, Revenue, and the Race for the Future: Intelligent Automation Is Powering the Next Wave of Growth
November 18, 2025

It’s hard to ignore just how quickly the world around us is changing. Packages arrive faster than ever, store shelves restock almost instantly, and behind the scenes, businesses are racing to keep up with expectations that seem to climb by the day. But as the workforce shrinks and pressure rises—including a projected shortage of…

Read More